Furthermore, inhibition of JNK activation by JNK antisense oligonucleotides (JNKAS) exerts different outcomes in different cancer cell types, inhibiting the growth of certain p53-deficient, but not p53-positive, tumor cells46, 47, 48. This evidence concerns the gene MAPK8 and cancer.